Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Serum amyloid A: A potential biomarker of lung disorders.

Vietri L, Fui A, Bergantini L, d'Alessandro M, Cameli P, Sestini P, Rottoli P, Bargagli E.

Respir Investig. 2019 Nov 7. pii: S2212-5345(19)30165-0. doi: 10.1016/j.resinv.2019.09.005. [Epub ahead of print] Review.

PMID:
31708467
2.

Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis.

Bennett D, Bargagli E, Bianchi N, Landi C, Fossi A, Fui A, Sestini P, Refini RM, Rottoli P.

Respir Physiol Neurobiol. 2019 Oct 30:103323. doi: 10.1016/j.resp.2019.103323. [Epub ahead of print]

PMID:
31678459
3.

Omalizumab treatment in Samter's triad: case series and review of the literature.

Cameli P, Perruzza M, Salvini M, Fui A, Cekorja B, Refini RM, Sestini P, Bargagli E.

Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):8124-8129. doi: 10.26355/eurrev_201909_19031.

4.

The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases.

Bargagli E, Cameli P, Carleo A, Refini RM, Bergantini L, D'alessandro M, Vietri L, Perillo F, Volterrani L, Rottoli P, Bini L, Landi C.

Panminerva Med. 2019 Sep 24. doi: 10.23736/S0031-0808.19.03754-6. [Epub ahead of print]

PMID:
31577091
5.

NK and NKT-like cells in granulomatous and fibrotic lung diseases.

Bergantini L, Cameli P, d'Alessandro M, Vagaggini C, Refini RM, Landi C, Pieroni MG, Spalletti M, Sestini P, Bargagli E.

Clin Exp Med. 2019 Nov;19(4):487-494. doi: 10.1007/s10238-019-00578-3. Epub 2019 Sep 4.

PMID:
31485847
6.

New concepts in the pathogenesis of sarcoidosis.

Bennett D, Bargagli E, Refini RM, Rottoli P.

Expert Rev Respir Med. 2019 Oct;13(10):981-991. doi: 10.1080/17476348.2019.1655401. Epub 2019 Aug 23.

PMID:
31414923
7.

Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis.

Cameli P, Carleo A, Bergantini L, Landi C, Prasse A, Bargagli E.

Inflammation. 2019 Jul 11. doi: 10.1007/s10753-019-01059-1. [Epub ahead of print] Review.

PMID:
31297749
8.

The Relevance of Family History Taking in the Detection and Management of Birt-Hogg-Dubé Syndrome.

Torricelli E, Occhipinti M, Cavigli E, Tancredi G, Rosi E, Rossi C, Bonaguro M, Candita L, Papi L, Novelli L, Bezzi M, Bargagli E, Voltolini L, Pistolesi M.

Respiration. 2019;98(2):125-132. doi: 10.1159/000498973. Epub 2019 Jul 2.

9.

Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?

Bargagli E, Mazzei MA, Orlandi M, Gentili F, Bellisai F, Frediani B, Bergantini L, Carobene L, Randone SB, Guiducci S, Cameli P, Bruni C, Cerinic MM.

Medicine (Baltimore). 2019 Jun;98(26):e16086. doi: 10.1097/MD.0000000000016086.

10.

Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis.

Cameli P, Bergantini L, Salvini M, Refini RM, Pieroni M, Bargagli E, Sestini P.

Nitric Oxide. 2019 Aug 1;89:41-45. doi: 10.1016/j.niox.2019.05.001. Epub 2019 May 2.

PMID:
31054949
11.

Serum amyloid A in patients with idiopathic pulmonary fibrosis.

Vietri L, Bennett D, Cameli P, Bergantini L, Cillis G, Sestini P, Bargagli E, Rottoli P.

Respir Investig. 2019 Sep;57(5):430-434. doi: 10.1016/j.resinv.2019.03.010. Epub 2019 Apr 26.

PMID:
31031123
12.

Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype?

Perruzza M, Fusha E, Cameli P, Capecchi PL, Selvi E, Gentili F, Mazzei MA, Aversa S, Spina D, Di Lucia D, Sestini P, Luzzi L, Bargagli E.

Respir Med Case Rep. 2019 Apr 17;27:100843. doi: 10.1016/j.rmcr.2019.100843. eCollection 2019.

13.

Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis.

Fui A, Bergantini L, Selvi E, Mazzei MA, Bennett D, Pieroni MG, Rottoli P, Bargagli E.

Intern Med J. 2019 Apr 9. doi: 10.1111/imj.14306. [Epub ahead of print]

PMID:
30963656
14.

Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6.

Bergantini L, Bianchi F, Cameli P, Mazzei MA, Fui A, Sestini P, Rottoli P, Bargagli E.

Dis Markers. 2019 Mar 3;2019:8565423. doi: 10.1155/2019/8565423. eCollection 2019.

15.

Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype?

Bianchi F, Piccioli C, Rosi E, Carobene L, Spina D, Mazzei MA, Bartolucci M, Moroni C, Novelli L, Rottoli P, Bargagli E.

Respir Med. 2019 Mar 16. pii: S0954-6111(19)30078-2. doi: 10.1016/j.rmed.2019.02.022. [Epub ahead of print] No abstract available.

PMID:
30922726
16.

Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib.

Bergantini L, Bargagli E, Cameli P, Cekorja B, Lanzarone N, Pianigiani L, Vietri L, Bennett D, Sestini P, Rottoli P.

Respir Investig. 2019 May;57(3):290-291. doi: 10.1016/j.resinv.2019.02.001. Epub 2019 Feb 21. No abstract available.

PMID:
30799155
17.

Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, Poletti V.

ERJ Open Res. 2019 Feb 18;5(1). pii: 00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb. Review.

18.

Diagnosis of idiopathic pulmonary fibrosis by virtual means using "IPFdatabase"- a new software.

Bennett D, Mazzei MA, Collins B, Bargagli E, Pipavath S, Spina D, Valentini ML, Rinaldi C, Bettini G, Ginori A, Refini RM, Rottoli P, Raghu G.

Respir Med. 2019 Feb;147:31-36. doi: 10.1016/j.rmed.2018.12.011. Epub 2019 Jan 3.

PMID:
30704696
19.

Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease.

Cameli P, Bargagli E, Bergantini L, Refini RM, Pieroni M, Sestini P, Rottoli P.

J Breath Res. 2019 Mar 27;13(2):026008. doi: 10.1088/1752-7163/ab0233.

PMID:
30690441
20.

Competence in transbronchial cryobiopsy.

Barisione E, Salio M, Romagnoli M, Praticò A, Bargagli E, Corbetta L.

Panminerva Med. 2019 Sep;61(3):290-297. doi: 10.23736/S0031-0808.18.03567-X. Epub 2018 Oct 31.

21.

The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis.

Bargagli E, Di Masi M, Perruzza M, Vietri L, Bergantini L, Torricelli E, Biadene G, Fontana G, Lavorini F.

Intern Emerg Med. 2019 Jan;14(1):39-43. doi: 10.1007/s11739-018-1960-5. Epub 2018 Sep 29. Review.

PMID:
30269188
22.

Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers.

Landi C, Bargagli E, Carleo A, Refini RM, Bennett D, Bianchi L, Cillis G, Prasse A, Bini L, Rottoli P.

Rheumatology (Oxford). 2019 Jan 1;58(1):165-178. doi: 10.1093/rheumatology/key223.

PMID:
30239835
23.

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.

Bargagli E, Piccioli C, Rosi E, Torricelli E, Turi L, Piccioli E, Pistolesi M, Ferrari K, Voltolini L.

Pulmonology. 2019 May - Jun;25(3):149-153. doi: 10.1016/j.pulmoe.2018.06.003. Epub 2018 Sep 17.

24.

Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity.

Bargagli E, Rottoli P, Torricelli E, Allegrini C, Dubini A, Bennett D, Luzzi L, Spina D, Poletti V, Tomassetti S.

Pathobiology. 2018;85(5-6):276-279. doi: 10.1159/000492431. Epub 2018 Sep 17.

PMID:
30223268
25.

BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis.

Prasse A, Binder H, Schupp JC, Kayser G, Bargagli E, Jaeger B, Hess M, Rittinghausen S, Vuga L, Lynn H, Violette S, Jung B, Quast K, Vanaudenaerde B, Xu Y, Hohlfeld JM, Krug N, Herazo-Maya JD, Rottoli P, Wuyts WA, Kaminski N.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):622-630. doi: 10.1164/rccm.201712-2551OC.

PMID:
30141961
26.

Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer.

Bargagli E, Bonti V, Bindi A, Scotti V, Pistolesi M, Voltolini L, Ferrari K.

Monaldi Arch Chest Dis. 2018 Jun 21;88(2):917. doi: 10.4081/monaldi.2018.917.

27.

Phenotypes of organ involvement in sarcoidosis.

Schupp JC, Freitag-Wolf S, Bargagli E, Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O'Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane MP, O'Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J.

Eur Respir J. 2018 Jan 25;51(1). pii: 1700991. doi: 10.1183/13993003.00991-2017. Print 2018 Jan.

28.

Sarcoidosis: a review for the internist.

Bargagli E, Prasse A.

Intern Emerg Med. 2018 Apr;13(3):325-331. doi: 10.1007/s11739-017-1778-6. Epub 2018 Jan 3. Review.

PMID:
29299831
29.

Immunoglobulin replacement therapy for yellow nail syndrome.

Lo Conte C, Allegrini C, Matucci A, Bartolucci M, Rosi E, Camiciottoli G, Amendola M, Pistolesi M, Bargagli E.

Scand J Immunol. 2018 Mar;87(3). doi: 10.1111/sji.12639. Epub 2018 Jan 10. No abstract available.

30.

Gorham-Stout Disease Management during Pregnancy.

Bargagli E, Piccioli C, Cavigli E, Scola M, Rosi E, Lavorini F, Novelli L, Ugolini D, Notaristefano T, Filippo P, Miele V, Comin CE, Pistolesi M, Voltolini L.

AJP Rep. 2017 Oct;7(4):e226-e229. doi: 10.1055/s-0037-1615259. Epub 2017 Dec 19.

31.

Atypical HRCT manifestations of pulmonary sarcoidosis.

Cozzi D, Bargagli E, Calabrò AG, Torricelli E, Giannelli F, Cavigli E, Miele V.

Radiol Med. 2018 Mar;123(3):174-184. doi: 10.1007/s11547-017-0830-y. Epub 2017 Nov 9.

PMID:
29124658
32.

Fibrotic Lung Toxicity Induced by Hydroxycarbamide.

Bargagli E, Palazzi M, Perri F, Torricelli E, Rosi E, Bindi A, Pistolesi M, Voltolini L.

In Vivo. 2017 Nov-Dec;31(6):1221-1223.

33.

Increased Risk of Atherosclerosis in Patients with Sarcoidosis.

Bargagli E, Rosi E, Pistolesi M, Lavorini F, Voltolini L, Rottoli P.

Pathobiology. 2017;84(5):258-263. doi: 10.1159/000477736. Epub 2017 Aug 10. Review.

34.

Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.

Bargagli E, Bonti V, Ferrari K, Rosi E, Bindi A, Bartolucci M, Chiara M, Voltolini L.

In Vivo. 2017 Jul-Aug;31(4):773-777.

35.

Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases.

Bargagli E, Lavorini F, Pistolesi M, Rosi E, Prasse A, Rota E, Voltolini L.

J Trace Elem Med Biol. 2017 Jul;42:39-44. doi: 10.1016/j.jtemb.2017.04.001. Epub 2017 Apr 5. Review.

PMID:
28595790
36.

Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns.

Bennett D, Mazzei MA, Squitieri NC, Bargagli E, Refini RM, Fossi A, Volterrani L, Rottoli P.

Respir Med. 2017 May;126:75-83. doi: 10.1016/j.rmed.2017.03.020. Epub 2017 Mar 22.

37.

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience.

Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M, Masieri S, Rolla G, Steinhilber G, Rosati Y, Vultaggio A, Folletti I, Baglioni S, Bargagli E, Di Tomassi M, Pio R, Pio A, Maccari U, Maggiorelli C, Migliorini MG, Vignale L, Pulerà N, Carpagnano GE, Foschino Barbaro MP, Perrella A, Paggiaro PL.

Respir Med. 2016 Oct;119:141-149. doi: 10.1016/j.rmed.2016.09.005. Epub 2016 Sep 4.

38.

Idiopathic pulmonary fibrosis a rare disease with severe bone fragility.

Caffarelli C, Gonnelli S, Tomai Pitinca MD, Francolini V, Fui A, Bargagli E, Refini RM, Bennett D, Nuti R, Rottoli P.

Intern Emerg Med. 2016 Dec;11(8):1087-1094. Epub 2016 Jul 8.

PMID:
27393142
39.

Macrophage migration inhibitory factor in lung tissue of idiopathic pulmonary fibrosis patients.

Olivieri C, Bargagli E, Inghilleri S, Campo I, Cintorino M, Rottoli P.

Exp Lung Res. 2016 Jun;42(5):263-6. doi: 10.1080/01902148.2016.1199744. Epub 2016 Jun 23.

PMID:
27337548
40.

Comparative proteomic analysis of bronchoalveolar lavage of familial and sporadic cases of idiopathic pulmonary fibrosis.

Carleo A, Bargagli E, Landi C, Bennett D, Bianchi L, Gagliardi A, Carnemolla C, Perari MG, Cillis G, Armini A, Bini L, Rottoli P.

J Breath Res. 2016 Apr 15;10(2):026007. doi: 10.1088/1752-7155/10/2/026007.

PMID:
27082636
41.

A functional proteomics approach to the comprehension of sarcoidosis.

Landi C, Bargagli E, Carleo A, Bianchi L, Gagliardi A, Cillis G, Perari MG, Refini RM, Prasse A, Bini L, Rottoli P.

J Proteomics. 2015 Oct 14;128:375-87. doi: 10.1016/j.jprot.2015.08.012. Epub 2015 Sep 2.

PMID:
26342673
42.

Exhaled nitric oxide and carbon monoxide in lung transplanted patients.

Cameli P, Bargagli E, Fossi A, Bennett D, Voltolini L, Refini RM, Gotti G, Rottoli P.

Respir Med. 2015 Sep;109(9):1224-9. doi: 10.1016/j.rmed.2015.07.005. Epub 2015 Jul 9.

43.

Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience.

Bennett D, Fossi A, Bargagli E, Refini RM, Pieroni M, Luzzi L, Ghiribelli C, Paladini P, Voltolini L, Rottoli P.

Lung. 2015 Oct;193(5):677-81. doi: 10.1007/s00408-015-9767-x. Epub 2015 Jul 28.

PMID:
26216722
44.

Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent.

Bennett D, Bargagli E, Refini RM, Pieroni MG, Fossi A, Romeo R, Volterrani L, Mazzei MA, Rottoli P.

Int J Occup Med Environ Health. 2015;28(4):775-9. doi: 10.13075/ijomeh.1896.00462.

45.

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.

Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, Tomassetti S, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M.

Respir Med. 2015 Jul;109(7):904-13. doi: 10.1016/j.rmed.2015.04.010. Epub 2015 Apr 25.

46.

A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls.

Landi C, Bargagli E, Carleo A, Bianchi L, Gagliardi A, Prasse A, Perari MG, Refini RM, Bini L, Rottoli P.

Proteomics Clin Appl. 2014 Dec;8(11-12):932-50. doi: 10.1002/prca.201400001. Epub 2014 Oct 22.

PMID:
25169739
47.

Exhaled nitric oxide in interstitial lung diseases.

Cameli P, Bargagli E, Refini RM, Pieroni MG, Bennett D, Rottoli P.

Respir Physiol Neurobiol. 2014 Jun 15;197:46-52. doi: 10.1016/j.resp.2014.03.011. Epub 2014 Apr 2.

PMID:
24703971
48.

Helicobacter pylori seroprevalence in patients with idiopathic pulmonary fibrosis.

Bennett D, Bargagli E, Refini RM, Campagna MS, Gennari L, Nuti R, Figura N, Rottoli P.

Eur Respir J. 2014 Feb;43(2):635-8. doi: 10.1183/09031936.00104813. Epub 2013 Oct 10. No abstract available.

49.

TLR7 Gln11Leu single nucleotide polymorphism in patients with sarcoidosis.

Bordignon M, Bargagli E, Agostini C, Cinetto F, Baldo V, Alaibac M, Rottoli P.

Sarcoidosis Vasc Diffuse Lung Dis. 2013 Aug 1;30(2):157-61.

PMID:
24071890
50.

Serum analysis of coagulation factors in IPF and NSIP.

Bargagli E, Madioni C, Bianchi N, Refini RM, Cappelli R, Rottoli P.

Inflammation. 2014 Feb;37(1):10-6. doi: 10.1007/s10753-013-9706-z.

PMID:
23912648

Supplemental Content

Loading ...
Support Center